6.34

2.76% -0.18

After Hours: 6.35 0.010 +0.16%

Lenz Therapeutics Inc (LENZ)

Overview News Price History Discussions Forecast

Lenz Therapeutics Inc stock is traded at $6.34, with a volume of 687.90K. It is down -2.76% in the last 24 hours and down -13.62% over the past month. LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Previous Close:

$6.52

Open:

$6.57

24h Volume:

687.90K

Relative Volume:

0.77

Market Cap:

$198.79M

Revenue:

$19.09M

Net Income/Loss:

$-82.13M

P/E Ratio:

-2.2622

EPS:

-2.8026

Net Cash Flow:

$-70.00M

1W Performance:

-3.65%

1M Performance:

-13.62%

6M Performance:

-61.27%

1Y Performance:

-78.11%

1-Day Range:

$6.29

$6.82

1-Week Range:

$6.285

$7.0929

52-Week Range:

$6.285

$50.40

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name

Lenz Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

858-925-7000

Address

201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH

Employee

152

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

LENZ's Discussions on Twitter

Compare LENZ vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LENZ Lenz Therapeutics Inc	6.34	207.88M	19.09M	-82.13M	-70.00M	-2.8026
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-25	Resumed	Piper Sandler	Overweight
Mar-18-25	Initiated	TD Cowen	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-12-24	Initiated	H.C. Wainwright	Buy
Apr-15-24	Initiated	Leerink Partners	Outperform
Apr-15-24	Initiated	William Blair	Outperform
Apr-10-24	Initiated	Citigroup	Buy
Mar-27-24	Initiated	Piper Sandler	Overweight
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-14-22	Initiated	BTIG Research	Buy
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform
Jul-20-21	Initiated	Morgan Stanley	Overweight
Jul-20-21	Initiated	SVB Leerink	Outperform

View All

Lenz Therapeutics Inc Stock (LENZ) Latest News

Jun 15, 2026

RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant - Stock Titan

Jun 15, 2026

LENZ (NASDAQ: LENZ) director awarded 22,100 stock options at $6.63 strike - Stock Titan

Jun 15, 2026

LENZ Therapeutics grants 22,100 options to director | LENZ Insider Trading - Stock Titan

Jun 15, 2026

Jun 12, 2026

Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting - Investing.com Australia

Jun 12, 2026

Everest medicines acquires greater china rights to aceclidine presbyopia eye drop (VIZZ) - Ophthalmology Times

Jun 08, 2026

Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ) - Ophthalmology Times

Jun 08, 2026

LENZ Therapeutics adds China partner for presbyopia drug VIZZ - Yahoo Finance

Jun 08, 2026

Everest Medicines acquires Greater China rights for LENZ Therapeutics' presbyopia eyedrop VIZZ® - MSN

Jun 08, 2026

LENZ Therapeutics to Receive VIZZ Payments From Everest-Corxel Deal - marketscreener.com

Jun 08, 2026

LENZ Therapeutics (LENZ) Stock Price, News & Analysis - MarketBeat

Jun 08, 2026

Jun 07, 2026

LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China - Quiver Quantitative

Jun 07, 2026

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ - LENZ Therapeutics

Jun 07, 2026

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China - The Norfolk Daily News

Jun 07, 2026

May 27, 2026

LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10 - MSN

May 27, 2026

May 26, 2026

Eye drop company LENZ heads to three investor conferences in June - Stock Titan

May 26, 2026

LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

May 26, 2026

May 19, 2026

Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026 By Investing.com - Investing.com Nigeria

May 19, 2026

May 17, 2026